Literature DB >> 7828539

Expression of a Trk high affinity nerve growth factor receptor in the human prostate.

B R Pflug1, C Dionne, D R Kaplan, J Lynch, D Djakiew.   

Abstract

Nerve growth factor-beta (NGF beta) and a NGF beta-immunoreactive protein derived from human prostatic stromal cell secretory protein (hPS) have been shown to stimulate the growth of prostate epithelial cells. An NGF beta-immunoreactive protein has been localized to the stroma of human prostate tissues, and a low affinity NGF receptor (gp75NGFR) has been localized to the adjacent epithelia, consistent with the paracrine regulation of prostate growth. Interestingly, gp75NGFR is progressively lost during neoplastic progression of the human prostate. In this report we have characterized the expression of the signal-transducing component of the NGF receptor, the Trk tyrosine receptor kinase, in prostate epithelial cells that bind exogenous NGF beta and an endogenous NGF beta-immunoreactive protein in hPS. In this context, a pan-Trk antibody that recognizes all of the members of the Trk receptor family (TrkA, TrkB, and TrkC) specifically localized expression of the Trk receptor to the epithelial component of normal prostate tissue, benign prostatic hyperplasia, and adenocarcinoma tissue. The binding of [125I]NGF beta to the surface of primary cultures of human prostate epithelia and the TSU-pr1 human metastatic prostate tumor cell line was displaced with either excess cold NGF beta or hPS, whereas binding was not displaced by epidermal growth factor or platelet-derived growth factor. Scatchard plot analysis of [125I]NGF beta binding to these cells identified a low affinity binding site (Kd = 1.9 x 10(-9) M) and a high affinity binding site (Kd = 1.8 x 10(-11) M) on the primary prostate epithelia, whereas only a high affinity binding site (Kd = 1.3 x 10(-11) M) was observed on the TSU-pr1 tumor cells. Stimulation of TSU-pr1 cells with either NGF beta or hPS induced tyrosine phosphorylation of Trk proteins, whereas no phosphorylation was evident in untreated cells, cells treated with hPS immunoprecipitated with anti-NGF beta antibody, or brain-derived neurotrophic factor- and neurotrophin-3-treated cells. The Trk protein was also observed in these cells by immunoblot analysis with pan-Trk antibody. These results demonstrate a functional Trk receptor in the epithelia of the human prostate that is responsive to exogenous NGF beta and an endogenous NGF beta-immunoreactive protein in hPS, thereby supporting the concept of the paracrine regulation of growth in the human prostate via a stromal neurotrophin-epithelial Trk receptor interaction.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7828539     DOI: 10.1210/endo.136.1.7828539

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  21 in total

1.  TrkB inhibition by GNF-4256 slows growth and enhances chemotherapeutic efficacy in neuroblastoma xenografts.

Authors:  Jamie L Croucher; Radhika Iyer; Nanxin Li; Valentina Molteni; Jon Loren; W Perry Gordon; Tove Tuntland; Bo Liu; Garrett M Brodeur
Journal:  Cancer Chemother Pharmacol       Date:  2014-11-14       Impact factor: 3.333

2.  AZ64 inhibits TrkB and enhances the efficacy of chemotherapy and local radiation in neuroblastoma xenografts.

Authors:  Radhika Iyer; Carly R Varela; Jane E Minturn; Ruth Ho; Anisha M Simpson; Jennifer E Light; Audrey E Evans; Huaqing Zhao; Kenneth Thress; Jeffrey L Brown; Garrett M Brodeur
Journal:  Cancer Chemother Pharmacol       Date:  2012-05-24       Impact factor: 3.333

Review 3.  On Trk--the TrkB signal transduction pathway is an increasingly important target in cancer biology.

Authors:  Carol J Thiele; Zhijie Li; Amy E McKee
Journal:  Clin Cancer Res       Date:  2009-09-15       Impact factor: 12.531

4.  Nerve growth factor stimulates in vitro invasive capacity of DU145 human prostatic cancer cells.

Authors:  A A Geldof; M A De Kleijn; B R Rao; D W Newling
Journal:  J Cancer Res Clin Oncol       Date:  1997       Impact factor: 4.553

5.  Role of neurotrophins and neurotrophins receptors in the in vitro invasion and heparanase production of human prostate cancer cells.

Authors:  E T Walch; D Marchetti
Journal:  Clin Exp Metastasis       Date:  1999-06       Impact factor: 5.150

6.  Nerve growth factor control of neuronal expression of angiogenetic and vasoactive factors.

Authors:  L Calza; L Giardino; A Giuliani; L Aloe; R Levi-Montalcini
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-20       Impact factor: 11.205

7.  Urinary nerve growth factor as an oncologic biomarker for prostate cancer aggressiveness.

Authors:  Michael A Liss; Adam Gordon; Blanca Morales; Kathryn Osann; Douglas Skarecky; Achim Lusch; Frank Zaldivar; Thomas E Ahlering
Journal:  Urol Oncol       Date:  2014-04-29       Impact factor: 3.498

8.  Repetitive transcranial magnetic stimulation enhances BDNF-TrkB signaling in both brain and lymphocyte.

Authors:  Hoau-Yan Wang; Domenica Crupi; Jingjing Liu; Andres Stucky; Giuseppe Cruciata; Alessandro Di Rocco; Eitan Friedman; Angelo Quartarone; M Felice Ghilardi
Journal:  J Neurosci       Date:  2011-07-27       Impact factor: 6.167

9.  TRAF-4 expression in epithelial progenitor cells. Analysis in normal adult, fetal, and tumor tissues.

Authors:  M Krajewska; S Krajewski; J M Zapata; T Van Arsdale; R D Gascoyne; K Berern; D McFadden; A Shabaik; J Hugh; A Reynolds; C V Clevenger; J C Reed
Journal:  Am J Pathol       Date:  1998-06       Impact factor: 4.307

10.  Phase I clinical trial of CEP-2563 dihydrochloride, a receptor tyrosine kinase inhibitor, in patients with refractory solid tumors.

Authors:  Samir D Undevia; Nicholas J Vogelzang; Ann M Mauer; Linda Janisch; Sridhar Mani; Mark J Ratain
Journal:  Invest New Drugs       Date:  2004-11       Impact factor: 3.850

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.